BCLI Overview

Financial Update: BrainStorm Cell Therapeutics reported a net loss of approximately $2.1 million for Q3 2025, a decrease from $2.7 million in Q3 2024, with cash reserves at about $0.23 million.

NurOwn Clinical Trial Progress: The company has received FDA clearance to initiate a Phase 3b clinical trial for NurOwn, aimed at generating data to support a Biologics License Application (BLA) for ALS treatment.

Community Engagement: A Citizen Petition from the ALS community has been filed to request a renewed regulatory review of NurOwn, which BrainStorm views as a positive development reflecting interest in the therapy's potential.

Future Plans: BrainStorm plans to host a conference call in late Q4 2025 or early Q1 2026 to provide updates on the NurOwn Phase 3 program and its ongoing efforts in the ALS community.

Alto Neuroscience Investigation: Grabar Law Office is investigating claims against Alto Neuroscience, Inc. for potential breaches of fiduciary duties by its officers and directors, following allegations of misleading statements regarding the effectiveness of its treatment ALTO-100.

Brainstorm Cell Therapeutics Update: An investigation is ongoing into Brainstorm Cell Therapeutics Inc. after key allegations in a securities fraud class action survived a motion to dismiss, concerning misleading statements about FDA feedback and clinical trial safety.

Flywire Corporation Claims: Grabar Law Office is looking into Flywire Corporation for possible breaches of fiduciary duties, as a securities fraud complaint alleges the company overstated its revenue growth and downplayed negative impacts from permit and visa restrictions.

Ibotta, Inc. Allegations: Ibotta, Inc. is under investigation for potentially misleading statements made during its IPO regarding the risks associated with its contract with Kroger, which was at-will and could be canceled without warning.